Veradigm (MDRX) announced an advancement in the use of artificial intelligence to scale the generation of real-world evidence for GLP-1 receptor agonists, including semaglutide and tirzepatide. By applying AI to electronic health record deidentified data within the Veradigm Network, researchers can now surface rich, contextual insights-such as side effects, discontinuation reasons, and social determinants of health-that traditionally required intensive manual curation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDRX: